×
Please click
here
if you are not redirected within a few seconds.
All
News
Maps
Images
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Thiel-backed psychedelics startup Atai valued at $3.19 bln in Nasdaq debut
Reuters
Shares of Atai Life Sciences B.V. (ATAI.O), backed by billionaire investor Peter Thiel, surged 40% in their U.S. stock market debut on...
35 months ago
After Falling 60% in 1 Year, Is Atai Life Sciences Stock Still a Buy?
The Motley Fool
With its shares down by 60% in the last 12 months and a recent layoff affecting 30% of its workforce, it's fair to say that Atai Life...
13 months ago
atai Life Sciences Announces Pricing of Upsized Initial Public Offering
Psychedelic Alpha
BERLIN, June 17, 2021 (GLOBE NEWSWIRE) — atai Life Sciences B.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform...
24 months ago
atai Life Sciences Announces Launch of Initial Public Offering
GlobeNewswire
BERLIN, June 11, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences B.V. (“atai”), a clinical-stage biopharmaceutical company aiming to transform...
35 months ago
The Unofficial Atai Life Sciences Pre-IPO Deep Dive: What Investors Need To Know
The Dales Report
Since its inception in 2018, atai Life Sciences B.V. has built a pipeline and advanced multiple therapeutic programs through both incubation...
35 months ago
New Venture Firm Adds to Surge in Psychedelic Investments
WSJ
Florida lawyer Dustin Robinson recently created Iter Investments to allocate capital for the development of psychedelic drugs.
37 months ago
German psychedelic startup Atai targets valuation of $2.3 bln in U.S. IPO
Reuters
Atai Life Sciences B.V., backed by billionaire investor Peter Thiel, said on Friday it was looking to raise as much as $214.3 million...
35 months ago
How AI could unlock the medical potential of psychedelics
Pharmaceutical Technology
Drug companies are employing artificial intelligence in their search for new psychedelic drugs to treat a range of conditions.
28 months ago
Why Psychedelics, Big in 1960s, Draw New Interest Now: QuickTake
Bloomberg
People have been blowing their minds with hallucinatory substances for millennia -- at least since the ancient Greeks drank a psychoactive...
37 months ago
UK drug discoverer Exscientia hits the big time with oversized Nasdaq IPO
BioWorld MedTech
Exscientia plc has raised $510.4 million in an upsized Nasdaq IPO and private funding round as it pushes forward with its artificial...
31 months ago